---
document_datetime: 2025-08-27 15:03:36
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/betmiga-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: betmiga-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.515356
conversion_datetime: 2025-12-22 18:00:05.705662
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Betmiga

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                       |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------|
| Variation type II /  | This was an application for a group of | 17/07/2025                          |                                             | SmPC and PL                      | Please refer to Scientific Discussion Betmiga |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000249016   | variations.                                  | EMA/VR/0000249016 For more information, please refer also to the Summary of Product   |
|---------------------|----------------------------------------------|---------------------------------------------------------------------------------------|
|                     | C.I HUMAN AND VETERINARY MEDICINAL           | Characteristics.                                                                      |
|                     | PRODUCTS - C.I.4 Change(s) in the            |                                                                                       |
|                     | Summary of Product Characteristics,          |                                                                                       |
|                     | Labelling or Package Leaflet due to new      |                                                                                       |
|                     | quality, preclinical, clinical or            |                                                                                       |
|                     | pharmacovigilance data - Accepted            |                                                                                       |
|                     | C.I HUMAN AND VETERINARY MEDICINAL           |                                                                                       |
|                     | PRODUCTS - C.I.4 Change(s) in the            |                                                                                       |
|                     | Summary of Product Characteristics,          |                                                                                       |
|                     | Labelling or Package Leaflet due to new      |                                                                                       |
|                     | quality, preclinical, clinical or            |                                                                                       |
|                     | pharmacovigilance data - Accepted            |                                                                                       |
|                     | A grouped application consisting of: C.I.4:  |                                                                                       |
|                     | Update of sections 4.8, and 5.1 of the SmPC  |                                                                                       |
|                     | in order to update clinical information on   |                                                                                       |
|                     | Overactive bladder in the paediatric         |                                                                                       |
|                     | population based on final results from study |                                                                                       |
|                     | 178-CL-204 listed as a category 3 study in   |                                                                                       |
|                     | the RMP; this is a phase 3, double-blind,    |                                                                                       |
|                     | randomized, multicenter, parallel group,     |                                                                                       |
|                     | placebo controlled sequential dose titration |                                                                                       |
|                     | study to evaluate efficacy, safety, and      |                                                                                       |
|                     | pharmacokinetics of mirabegron in pediatric  |                                                                                       |
|                     | subjects from 5 to < 18 years of age with    |                                                                                       |
|                     | overactive bladder. In addition, the MAH     |                                                                                       |
|                     | took the opportunity to bring editorial      |                                                                                       |
|                     | changes to the PI. C.I.4: Update of section  |                                                                                       |
|                     | 5.3 of the SmPC in order to update non-      |                                                                                       |

<div style=\"page-break-after: always\"></div>

| clinical information based on results from previously submitted studies.   |
|----------------------------------------------------------------------------|